Replimune Group, Inc. (REPL)

NMS – Real Time Price. Currency in USD

4.47

+0.38 (9.41%)

Market open: May 13, 2026, 9:55 AM EDT

12.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

07.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

05.05.2026

What's Going On With Replimune Stock On Tuesday?

U.S. Food and Drug Administration (FDA) Commissioner Marty Makary defended his leadership in a CNBC interview aired Tuesday, growing criticism with concerns centering on drug approval decisions and internal leadership disputes that have sparked political and public backlash.

05.05.2026

FDA Commissioner Makary defends agency's decision on Replimune's drug

U.S. Food and Drug Administration Commissioner Dr. ‌Marty Makary on Tuesday defended the agency's decision to not approve ⁠Replimune's drug for advanced skin cancer.

01.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

28.04.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

22.04.2026

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's ‌decision to not approve Replimune's drug for advanced skin cancer, saying it was in the hands of the agency's Commissioner Dr. Marty Makary.

Videos

13.04.2026

Negative

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Press releases

12.05.2026

Replimune Group, Inc. (REPL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Replimune Group, Inc. (REPL)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

What's Going On With Replimune Stock On Tuesday?

FDA Commissioner Makary defends agency's decision on Replimune's drug

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Videos

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

What's Going On With Replimune Stock On Tuesday?

FDA Commissioner Makary defends agency's decision on Replimune's drug

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Videos

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

Search stocks

Replimune Group, Inc. (REPL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Replimune Group, Inc. (REPL)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

What's Going On With Replimune Stock On Tuesday?

FDA Commissioner Makary defends agency's decision on Replimune's drug

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Videos

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

What's Going On With Replimune Stock On Tuesday?

FDA Commissioner Makary defends agency's decision on Replimune's drug

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Videos

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL